Search Results - "Harrer, Dennis C"

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma by Harrer, Dennis C, Simon, Bianca, Fujii, Shin-Ichiro, Shimizu, Kanako, Uslu, Ugur, Schuler, Gerold, Gerer, Kerstin F, Hoyer, Stefanie, Dörrie, Jan, Schaft, Niels

“…Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial…”
Get full text

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia by Harrer, Dennis C, Schuler, Gerold, Dörrie, Jan, Schaft, Niels

“…The advent of CD19-specific chimeric antigen receptor (CAR) T cells has proven to be a powerful asset in the arsenal of cancer immunotherapy of acute…”
Get full text

Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies by Perl, Markus, Herfeld, Konstantin, Harrer, Dennis C, Höpting, Matthias, Schweiger, Marina, Sterz, Ulrich, Knödler, Leonard, Heimerl, Susanne, Hansmann, Leo, Herr, Wolfgang, Poeck, Hendrik, Wolff, Daniel, Edinger, Matthias, Hart, Christina, Fante, Matthias A

“…Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated…”
Get full text

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma by Fante, Matthias A, Harrer, Dennis C, Zartner, Barbara, Lüke, Florian, Mayer, Stephanie, Menhart, Karin, Reichle, Albrecht, Herr, Wolfgang, Vogelhuber, Martin, Heudobler, Daniel

“…Peripheral T-cell lymphoma (PTCL) is a rare and heterogenous hematologic malignancy with poor prognosis especially in elderly and frail patients who are not…”
Get full text

Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy by Lüke, Florian, Harrer, Dennis C., Hahn, Joachim, Grube, Matthias, Pukrop, Tobias, Herr, Wolfgang, Reichle, Albrecht, Heudobler, Daniel

“…Spontaneous remission in acute lymphoblastic leukemia (ALL) is a rare phenomenon, which typically involves a pattern of feverish or septic disease followed by…”
Get full text

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease by Lüke, Florian, Harrer, Dennis C., Menhart, Karin, Wolff, Daniel, Holler, Ernst, Hellwig, Dirk, Herr, Wolfgang, Grube, Matthias, Vogelhuber, Martin, Reichle, Albrecht, Heudobler, Daniel

“…Introduction: Current combined intensive chemotherapy and radiation regimens yield excellent survival rates in advanced classic Hodgkin’s lymphoma (cHL)…”
Get full text

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges by Harrer, Dennis C, Dörrie, Jan, Schaft, Niels

“…Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable…”
Get full text

Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race by Harrer, Dennis C, Dörrie, Jan, Schaft, Niels

“…Adoptive cellular therapy has evolved into a powerful force in the battle against cancer, holding promise for curative responses in patients with advanced and…”
Get more information

The siRNA‐mediated downregulation of PD‐1 alone or simultaneously with CTLA‐4 shows enhanced in vitro CAR‐T‐cell functionality for further clinical development towards the potential use in immunotherapy of melanoma by Simon, Bianca, Harrer, Dennis C., Schuler‐Thurner, Beatrice, Schaft, Niels, Schuler, Gerold, Dörrie, Jan, Uslu, Ugur

“…Chimeric antigen receptor (CAR)‐T cells have been used successfully for cancer immunotherapy. While substantial tumor regression was observed in leukaemia and…”
Get full text

Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy by Simon, Bianca, Harrer, Dennis C., Thirion, Christian, Schuler-Thurner, Beatrice, Schuler, Gerold, Uslu, Ugur

“…Introduction of a tumor antigen-specific T cell receptor (TCR) into patient-derived lymphocytes has already exhibited promising results for the treatment of…”
Get full text

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer by Simon, Bianca, Harrer, Dennis C, Schuler-Thurner, Beatrice, Schuler, Gerold, Uslu, Ugur

“…Tumor cells can develop immune escape mechanisms to bypass T cell recognition, e.g., antigen loss or downregulation of the antigen presenting machinery, which…”
Get full text

Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis by Harrer, Dennis C., Jakob, Marcus, Vogelhuber, Martin, Lüke, Florian, Utpatel, Kirsten, Corbacioglu, Selim, Herr, Wolfgang, Reichle, Albrecht, Heudobler, Daniel

“…Langerhans cell histiocytosis (LCH) is rare hematological neoplasia originating from the aberrant proliferation of CD207-positive dendritic cells. Refractory…”
Get full text

The si RNA ‐mediated downregulation of PD ‐1 alone or simultaneously with CTLA ‐4 shows enhanced in vitro CAR ‐T‐cell functionality for further clinical development towards the potential use in immunotherapy of melanoma by Simon, Bianca, Harrer, Dennis C., Schuler‐Thurner, Beatrice, Schaft, Niels, Schuler, Gerold, Dörrie, Jan, Uslu, Ugur

“…Abstract Chimeric antigen receptor ( CAR )‐T cells have been used successfully for cancer immunotherapy. While substantial tumor regression was observed in…”
Get full text

RNA-transfection of [gamma]/[delta] T cells with a chimeric antigen receptor or an [alpha]/[beta] T-cell receptor: a safer alternative to genetically engineered [alpha]/[beta] T cells for the immunotherapy of melanoma by Harrer, Dennis C, Simon, Bianca, Fujii, Shin-ichiro, Shimizu, Kanako, Uslu, Ugur, Schuler, Gerold, Gerer, Kerstin F, Hoyer, Stefanie, Dörrie, Jan, Schaft, Niels

“…Background Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused…”
Get full text